Allogeneic hematopoietic stem cell transplantation is considered a curative option for some pediatric patients with high-risk malignancies. However, a significant fraction of these patients lack a suitable human leukocyte antigen (HLA) matched donor, or are met with an unacceptable delay in determining donor availability. For patients needing an allogeneic transplant in a timely manner, the use of haploidentical related donors is considered a suitable approach. "Ex-vivo" T-cell-depleted haploidentical transplant provides a valid platform for cellular therapy to enhance immune reconstitution, prevent or treat opportunistic infections and reduce the risk of relapse after transplant.
"Ex-vivo" T-cell-depleted haploidentical transplantation is now widely used, especially for pediatric patients with high-risk hematological malignancies and some pediatric solid tumors. However, relapsed disease and life-threatening viral infections are still important clinical problems as a consequence of delayed immune reconstitution. Adoptive cell therapies have been proposed and are being tested as a means to overcome these problems. Post-transplant cell therapies are based on the use of either NK-cells or subset of T-cells, such as regulatory T-cells or memory T-cells. Currently, the rapid development of graft manipulation techniques allows clinicians to test the development of new transplant and post-transplant strategies in order to improve transplant outcomes.
The present Research Topic is focused on haploidentical transplantation in children with malignancies (hematological and solid tumors). The scope includes not only the haploidentical transplantation strategy itself but also related topics such as post-transplant cellular therapy including DLI or CAR-NK cell therapy, and others. Reviews, basic advances and clinical papers are welcome.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Allogeneic hematopoietic stem cell transplantation is considered a curative option for some pediatric patients with high-risk malignancies. However, a significant fraction of these patients lack a suitable human leukocyte antigen (HLA) matched donor, or are met with an unacceptable delay in determining donor availability. For patients needing an allogeneic transplant in a timely manner, the use of haploidentical related donors is considered a suitable approach. "Ex-vivo" T-cell-depleted haploidentical transplant provides a valid platform for cellular therapy to enhance immune reconstitution, prevent or treat opportunistic infections and reduce the risk of relapse after transplant.
"Ex-vivo" T-cell-depleted haploidentical transplantation is now widely used, especially for pediatric patients with high-risk hematological malignancies and some pediatric solid tumors. However, relapsed disease and life-threatening viral infections are still important clinical problems as a consequence of delayed immune reconstitution. Adoptive cell therapies have been proposed and are being tested as a means to overcome these problems. Post-transplant cell therapies are based on the use of either NK-cells or subset of T-cells, such as regulatory T-cells or memory T-cells. Currently, the rapid development of graft manipulation techniques allows clinicians to test the development of new transplant and post-transplant strategies in order to improve transplant outcomes.
The present Research Topic is focused on haploidentical transplantation in children with malignancies (hematological and solid tumors). The scope includes not only the haploidentical transplantation strategy itself but also related topics such as post-transplant cellular therapy including DLI or CAR-NK cell therapy, and others. Reviews, basic advances and clinical papers are welcome.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
